Medical Care
Global Direct-acting Antiviral Drugs Market Research Report 2025
- Jul 08, 25
- ID: 347745
- Pages: 87
- Figures: 89
- Views: 1
The global market for Direct-acting Antiviral Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Direct-acting Antiviral Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Direct-acting Antiviral Drugs.
The Direct-acting Antiviral Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Direct-acting Antiviral Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Direct-acting Antiviral Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie Inc.
GSK
Boehringer Ingelheim
Merck
Novartis
Beximco Pharmaceuticals
Roche
Bristol-Myers Squibb Company
Gilead Sciences
Janssen (Johnson & Johnson)
Vertex Pharmaceuticals
Natco Pharma
Segment by Type
NS3/4A Protease Inhibitors
Nucleoside and Nucleotide NS5B Polymerase Inhibitors
NS5A Inhibitors
Non-Nucleoside NS5B Polymerase Inhibitors
Segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers
Pharmacies
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Direct-acting Antiviral Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Direct-acting Antiviral Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Direct-acting Antiviral Drugs.
The Direct-acting Antiviral Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Direct-acting Antiviral Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Direct-acting Antiviral Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie Inc.
GSK
Boehringer Ingelheim
Merck
Novartis
Beximco Pharmaceuticals
Roche
Bristol-Myers Squibb Company
Gilead Sciences
Janssen (Johnson & Johnson)
Vertex Pharmaceuticals
Natco Pharma
Segment by Type
NS3/4A Protease Inhibitors
Nucleoside and Nucleotide NS5B Polymerase Inhibitors
NS5A Inhibitors
Non-Nucleoside NS5B Polymerase Inhibitors
Segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers
Pharmacies
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Direct-acting Antiviral Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Direct-acting Antiviral Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 NS3/4A Protease Inhibitors
1.2.3 Nucleoside and Nucleotide NS5B Polymerase Inhibitors
1.2.4 NS5A Inhibitors
1.2.5 Non-Nucleoside NS5B Polymerase Inhibitors
1.3 Market by Application
1.3.1 Global Direct-acting Antiviral Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.3.5 Pharmacies
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Direct-acting Antiviral Drugs Market Perspective (2020-2031)
2.2 Global Direct-acting Antiviral Drugs Growth Trends by Region
2.2.1 Global Direct-acting Antiviral Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Direct-acting Antiviral Drugs Historic Market Size by Region (2020-2025)
2.2.3 Direct-acting Antiviral Drugs Forecasted Market Size by Region (2026-2031)
2.3 Direct-acting Antiviral Drugs Market Dynamics
2.3.1 Direct-acting Antiviral Drugs Industry Trends
2.3.2 Direct-acting Antiviral Drugs Market Drivers
2.3.3 Direct-acting Antiviral Drugs Market Challenges
2.3.4 Direct-acting Antiviral Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Direct-acting Antiviral Drugs Players by Revenue
3.1.1 Global Top Direct-acting Antiviral Drugs Players by Revenue (2020-2025)
3.1.2 Global Direct-acting Antiviral Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Direct-acting Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Direct-acting Antiviral Drugs Revenue
3.4 Global Direct-acting Antiviral Drugs Market Concentration Ratio
3.4.1 Global Direct-acting Antiviral Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Direct-acting Antiviral Drugs Revenue in 2024
3.5 Global Key Players of Direct-acting Antiviral Drugs Head office and Area Served
3.6 Global Key Players of Direct-acting Antiviral Drugs, Product and Application
3.7 Global Key Players of Direct-acting Antiviral Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Direct-acting Antiviral Drugs Breakdown Data by Type
4.1 Global Direct-acting Antiviral Drugs Historic Market Size by Type (2020-2025)
4.2 Global Direct-acting Antiviral Drugs Forecasted Market Size by Type (2026-2031)
5 Direct-acting Antiviral Drugs Breakdown Data by Application
5.1 Global Direct-acting Antiviral Drugs Historic Market Size by Application (2020-2025)
5.2 Global Direct-acting Antiviral Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Direct-acting Antiviral Drugs Market Size (2020-2031)
6.2 North America Direct-acting Antiviral Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Direct-acting Antiviral Drugs Market Size by Country (2020-2025)
6.4 North America Direct-acting Antiviral Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Direct-acting Antiviral Drugs Market Size (2020-2031)
7.2 Europe Direct-acting Antiviral Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Direct-acting Antiviral Drugs Market Size by Country (2020-2025)
7.4 Europe Direct-acting Antiviral Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Direct-acting Antiviral Drugs Market Size (2020-2031)
8.2 Asia-Pacific Direct-acting Antiviral Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Direct-acting Antiviral Drugs Market Size (2020-2031)
9.2 Latin America Direct-acting Antiviral Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Direct-acting Antiviral Drugs Market Size by Country (2020-2025)
9.4 Latin America Direct-acting Antiviral Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Direct-acting Antiviral Drugs Market Size (2020-2031)
10.2 Middle East & Africa Direct-acting Antiviral Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie Inc.
11.1.1 AbbVie Inc. Company Details
11.1.2 AbbVie Inc. Business Overview
11.1.3 AbbVie Inc. Direct-acting Antiviral Drugs Introduction
11.1.4 AbbVie Inc. Revenue in Direct-acting Antiviral Drugs Business (2020-2025)
11.1.5 AbbVie Inc. Recent Development
11.2 GSK
11.2.1 GSK Company Details
11.2.2 GSK Business Overview
11.2.3 GSK Direct-acting Antiviral Drugs Introduction
11.2.4 GSK Revenue in Direct-acting Antiviral Drugs Business (2020-2025)
11.2.5 GSK Recent Development
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Company Details
11.3.2 Boehringer Ingelheim Business Overview
11.3.3 Boehringer Ingelheim Direct-acting Antiviral Drugs Introduction
11.3.4 Boehringer Ingelheim Revenue in Direct-acting Antiviral Drugs Business (2020-2025)
11.3.5 Boehringer Ingelheim Recent Development
11.4 Merck
11.4.1 Merck Company Details
11.4.2 Merck Business Overview
11.4.3 Merck Direct-acting Antiviral Drugs Introduction
11.4.4 Merck Revenue in Direct-acting Antiviral Drugs Business (2020-2025)
11.4.5 Merck Recent Development
11.5 Novartis
11.5.1 Novartis Company Details
11.5.2 Novartis Business Overview
11.5.3 Novartis Direct-acting Antiviral Drugs Introduction
11.5.4 Novartis Revenue in Direct-acting Antiviral Drugs Business (2020-2025)
11.5.5 Novartis Recent Development
11.6 Beximco Pharmaceuticals
11.6.1 Beximco Pharmaceuticals Company Details
11.6.2 Beximco Pharmaceuticals Business Overview
11.6.3 Beximco Pharmaceuticals Direct-acting Antiviral Drugs Introduction
11.6.4 Beximco Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2020-2025)
11.6.5 Beximco Pharmaceuticals Recent Development
11.7 Roche
11.7.1 Roche Company Details
11.7.2 Roche Business Overview
11.7.3 Roche Direct-acting Antiviral Drugs Introduction
11.7.4 Roche Revenue in Direct-acting Antiviral Drugs Business (2020-2025)
11.7.5 Roche Recent Development
11.8 Bristol-Myers Squibb Company
11.8.1 Bristol-Myers Squibb Company Company Details
11.8.2 Bristol-Myers Squibb Company Business Overview
11.8.3 Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Introduction
11.8.4 Bristol-Myers Squibb Company Revenue in Direct-acting Antiviral Drugs Business (2020-2025)
11.8.5 Bristol-Myers Squibb Company Recent Development
11.9 Gilead Sciences
11.9.1 Gilead Sciences Company Details
11.9.2 Gilead Sciences Business Overview
11.9.3 Gilead Sciences Direct-acting Antiviral Drugs Introduction
11.9.4 Gilead Sciences Revenue in Direct-acting Antiviral Drugs Business (2020-2025)
11.9.5 Gilead Sciences Recent Development
11.10 Janssen (Johnson & Johnson)
11.10.1 Janssen (Johnson & Johnson) Company Details
11.10.2 Janssen (Johnson & Johnson) Business Overview
11.10.3 Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Introduction
11.10.4 Janssen (Johnson & Johnson) Revenue in Direct-acting Antiviral Drugs Business (2020-2025)
11.10.5 Janssen (Johnson & Johnson) Recent Development
11.11 Vertex Pharmaceuticals
11.11.1 Vertex Pharmaceuticals Company Details
11.11.2 Vertex Pharmaceuticals Business Overview
11.11.3 Vertex Pharmaceuticals Direct-acting Antiviral Drugs Introduction
11.11.4 Vertex Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2020-2025)
11.11.5 Vertex Pharmaceuticals Recent Development
11.12 Natco Pharma
11.12.1 Natco Pharma Company Details
11.12.2 Natco Pharma Business Overview
11.12.3 Natco Pharma Direct-acting Antiviral Drugs Introduction
11.12.4 Natco Pharma Revenue in Direct-acting Antiviral Drugs Business (2020-2025)
11.12.5 Natco Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Direct-acting Antiviral Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 NS3/4A Protease Inhibitors
1.2.3 Nucleoside and Nucleotide NS5B Polymerase Inhibitors
1.2.4 NS5A Inhibitors
1.2.5 Non-Nucleoside NS5B Polymerase Inhibitors
1.3 Market by Application
1.3.1 Global Direct-acting Antiviral Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.3.5 Pharmacies
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Direct-acting Antiviral Drugs Market Perspective (2020-2031)
2.2 Global Direct-acting Antiviral Drugs Growth Trends by Region
2.2.1 Global Direct-acting Antiviral Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Direct-acting Antiviral Drugs Historic Market Size by Region (2020-2025)
2.2.3 Direct-acting Antiviral Drugs Forecasted Market Size by Region (2026-2031)
2.3 Direct-acting Antiviral Drugs Market Dynamics
2.3.1 Direct-acting Antiviral Drugs Industry Trends
2.3.2 Direct-acting Antiviral Drugs Market Drivers
2.3.3 Direct-acting Antiviral Drugs Market Challenges
2.3.4 Direct-acting Antiviral Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Direct-acting Antiviral Drugs Players by Revenue
3.1.1 Global Top Direct-acting Antiviral Drugs Players by Revenue (2020-2025)
3.1.2 Global Direct-acting Antiviral Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Direct-acting Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Direct-acting Antiviral Drugs Revenue
3.4 Global Direct-acting Antiviral Drugs Market Concentration Ratio
3.4.1 Global Direct-acting Antiviral Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Direct-acting Antiviral Drugs Revenue in 2024
3.5 Global Key Players of Direct-acting Antiviral Drugs Head office and Area Served
3.6 Global Key Players of Direct-acting Antiviral Drugs, Product and Application
3.7 Global Key Players of Direct-acting Antiviral Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Direct-acting Antiviral Drugs Breakdown Data by Type
4.1 Global Direct-acting Antiviral Drugs Historic Market Size by Type (2020-2025)
4.2 Global Direct-acting Antiviral Drugs Forecasted Market Size by Type (2026-2031)
5 Direct-acting Antiviral Drugs Breakdown Data by Application
5.1 Global Direct-acting Antiviral Drugs Historic Market Size by Application (2020-2025)
5.2 Global Direct-acting Antiviral Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Direct-acting Antiviral Drugs Market Size (2020-2031)
6.2 North America Direct-acting Antiviral Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Direct-acting Antiviral Drugs Market Size by Country (2020-2025)
6.4 North America Direct-acting Antiviral Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Direct-acting Antiviral Drugs Market Size (2020-2031)
7.2 Europe Direct-acting Antiviral Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Direct-acting Antiviral Drugs Market Size by Country (2020-2025)
7.4 Europe Direct-acting Antiviral Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Direct-acting Antiviral Drugs Market Size (2020-2031)
8.2 Asia-Pacific Direct-acting Antiviral Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Direct-acting Antiviral Drugs Market Size (2020-2031)
9.2 Latin America Direct-acting Antiviral Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Direct-acting Antiviral Drugs Market Size by Country (2020-2025)
9.4 Latin America Direct-acting Antiviral Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Direct-acting Antiviral Drugs Market Size (2020-2031)
10.2 Middle East & Africa Direct-acting Antiviral Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie Inc.
11.1.1 AbbVie Inc. Company Details
11.1.2 AbbVie Inc. Business Overview
11.1.3 AbbVie Inc. Direct-acting Antiviral Drugs Introduction
11.1.4 AbbVie Inc. Revenue in Direct-acting Antiviral Drugs Business (2020-2025)
11.1.5 AbbVie Inc. Recent Development
11.2 GSK
11.2.1 GSK Company Details
11.2.2 GSK Business Overview
11.2.3 GSK Direct-acting Antiviral Drugs Introduction
11.2.4 GSK Revenue in Direct-acting Antiviral Drugs Business (2020-2025)
11.2.5 GSK Recent Development
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Company Details
11.3.2 Boehringer Ingelheim Business Overview
11.3.3 Boehringer Ingelheim Direct-acting Antiviral Drugs Introduction
11.3.4 Boehringer Ingelheim Revenue in Direct-acting Antiviral Drugs Business (2020-2025)
11.3.5 Boehringer Ingelheim Recent Development
11.4 Merck
11.4.1 Merck Company Details
11.4.2 Merck Business Overview
11.4.3 Merck Direct-acting Antiviral Drugs Introduction
11.4.4 Merck Revenue in Direct-acting Antiviral Drugs Business (2020-2025)
11.4.5 Merck Recent Development
11.5 Novartis
11.5.1 Novartis Company Details
11.5.2 Novartis Business Overview
11.5.3 Novartis Direct-acting Antiviral Drugs Introduction
11.5.4 Novartis Revenue in Direct-acting Antiviral Drugs Business (2020-2025)
11.5.5 Novartis Recent Development
11.6 Beximco Pharmaceuticals
11.6.1 Beximco Pharmaceuticals Company Details
11.6.2 Beximco Pharmaceuticals Business Overview
11.6.3 Beximco Pharmaceuticals Direct-acting Antiviral Drugs Introduction
11.6.4 Beximco Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2020-2025)
11.6.5 Beximco Pharmaceuticals Recent Development
11.7 Roche
11.7.1 Roche Company Details
11.7.2 Roche Business Overview
11.7.3 Roche Direct-acting Antiviral Drugs Introduction
11.7.4 Roche Revenue in Direct-acting Antiviral Drugs Business (2020-2025)
11.7.5 Roche Recent Development
11.8 Bristol-Myers Squibb Company
11.8.1 Bristol-Myers Squibb Company Company Details
11.8.2 Bristol-Myers Squibb Company Business Overview
11.8.3 Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Introduction
11.8.4 Bristol-Myers Squibb Company Revenue in Direct-acting Antiviral Drugs Business (2020-2025)
11.8.5 Bristol-Myers Squibb Company Recent Development
11.9 Gilead Sciences
11.9.1 Gilead Sciences Company Details
11.9.2 Gilead Sciences Business Overview
11.9.3 Gilead Sciences Direct-acting Antiviral Drugs Introduction
11.9.4 Gilead Sciences Revenue in Direct-acting Antiviral Drugs Business (2020-2025)
11.9.5 Gilead Sciences Recent Development
11.10 Janssen (Johnson & Johnson)
11.10.1 Janssen (Johnson & Johnson) Company Details
11.10.2 Janssen (Johnson & Johnson) Business Overview
11.10.3 Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Introduction
11.10.4 Janssen (Johnson & Johnson) Revenue in Direct-acting Antiviral Drugs Business (2020-2025)
11.10.5 Janssen (Johnson & Johnson) Recent Development
11.11 Vertex Pharmaceuticals
11.11.1 Vertex Pharmaceuticals Company Details
11.11.2 Vertex Pharmaceuticals Business Overview
11.11.3 Vertex Pharmaceuticals Direct-acting Antiviral Drugs Introduction
11.11.4 Vertex Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2020-2025)
11.11.5 Vertex Pharmaceuticals Recent Development
11.12 Natco Pharma
11.12.1 Natco Pharma Company Details
11.12.2 Natco Pharma Business Overview
11.12.3 Natco Pharma Direct-acting Antiviral Drugs Introduction
11.12.4 Natco Pharma Revenue in Direct-acting Antiviral Drugs Business (2020-2025)
11.12.5 Natco Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Direct-acting Antiviral Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of NS3/4A Protease Inhibitors
Table 3. Key Players of Nucleoside and Nucleotide NS5B Polymerase Inhibitors
Table 4. Key Players of NS5A Inhibitors
Table 5. Key Players of Non-Nucleoside NS5B Polymerase Inhibitors
Table 6. Global Direct-acting Antiviral Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Direct-acting Antiviral Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Direct-acting Antiviral Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Direct-acting Antiviral Drugs Market Share by Region (2020-2025)
Table 10. Global Direct-acting Antiviral Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Direct-acting Antiviral Drugs Market Share by Region (2026-2031)
Table 12. Direct-acting Antiviral Drugs Market Trends
Table 13. Direct-acting Antiviral Drugs Market Drivers
Table 14. Direct-acting Antiviral Drugs Market Challenges
Table 15. Direct-acting Antiviral Drugs Market Restraints
Table 16. Global Direct-acting Antiviral Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Direct-acting Antiviral Drugs Market Share by Players (2020-2025)
Table 18. Global Top Direct-acting Antiviral Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Direct-acting Antiviral Drugs as of 2024)
Table 19. Ranking of Global Top Direct-acting Antiviral Drugs Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Direct-acting Antiviral Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Direct-acting Antiviral Drugs, Headquarters and Area Served
Table 22. Global Key Players of Direct-acting Antiviral Drugs, Product and Application
Table 23. Global Key Players of Direct-acting Antiviral Drugs, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Direct-acting Antiviral Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Direct-acting Antiviral Drugs Revenue Market Share by Type (2020-2025)
Table 27. Global Direct-acting Antiviral Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Direct-acting Antiviral Drugs Revenue Market Share by Type (2026-2031)
Table 29. Global Direct-acting Antiviral Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Direct-acting Antiviral Drugs Revenue Market Share by Application (2020-2025)
Table 31. Global Direct-acting Antiviral Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Direct-acting Antiviral Drugs Revenue Market Share by Application (2026-2031)
Table 33. North America Direct-acting Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Direct-acting Antiviral Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Direct-acting Antiviral Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Direct-acting Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Direct-acting Antiviral Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Direct-acting Antiviral Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Direct-acting Antiviral Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Direct-acting Antiviral Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Direct-acting Antiviral Drugs Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Direct-acting Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Direct-acting Antiviral Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Direct-acting Antiviral Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Direct-acting Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 48. AbbVie Inc. Company Details
Table 49. AbbVie Inc. Business Overview
Table 50. AbbVie Inc. Direct-acting Antiviral Drugs Product
Table 51. AbbVie Inc. Revenue in Direct-acting Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 52. AbbVie Inc. Recent Development
Table 53. GSK Company Details
Table 54. GSK Business Overview
Table 55. GSK Direct-acting Antiviral Drugs Product
Table 56. GSK Revenue in Direct-acting Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 57. GSK Recent Development
Table 58. Boehringer Ingelheim Company Details
Table 59. Boehringer Ingelheim Business Overview
Table 60. Boehringer Ingelheim Direct-acting Antiviral Drugs Product
Table 61. Boehringer Ingelheim Revenue in Direct-acting Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 62. Boehringer Ingelheim Recent Development
Table 63. Merck Company Details
Table 64. Merck Business Overview
Table 65. Merck Direct-acting Antiviral Drugs Product
Table 66. Merck Revenue in Direct-acting Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 67. Merck Recent Development
Table 68. Novartis Company Details
Table 69. Novartis Business Overview
Table 70. Novartis Direct-acting Antiviral Drugs Product
Table 71. Novartis Revenue in Direct-acting Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 72. Novartis Recent Development
Table 73. Beximco Pharmaceuticals Company Details
Table 74. Beximco Pharmaceuticals Business Overview
Table 75. Beximco Pharmaceuticals Direct-acting Antiviral Drugs Product
Table 76. Beximco Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 77. Beximco Pharmaceuticals Recent Development
Table 78. Roche Company Details
Table 79. Roche Business Overview
Table 80. Roche Direct-acting Antiviral Drugs Product
Table 81. Roche Revenue in Direct-acting Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 82. Roche Recent Development
Table 83. Bristol-Myers Squibb Company Company Details
Table 84. Bristol-Myers Squibb Company Business Overview
Table 85. Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Product
Table 86. Bristol-Myers Squibb Company Revenue in Direct-acting Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 87. Bristol-Myers Squibb Company Recent Development
Table 88. Gilead Sciences Company Details
Table 89. Gilead Sciences Business Overview
Table 90. Gilead Sciences Direct-acting Antiviral Drugs Product
Table 91. Gilead Sciences Revenue in Direct-acting Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 92. Gilead Sciences Recent Development
Table 93. Janssen (Johnson & Johnson) Company Details
Table 94. Janssen (Johnson & Johnson) Business Overview
Table 95. Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Product
Table 96. Janssen (Johnson & Johnson) Revenue in Direct-acting Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 97. Janssen (Johnson & Johnson) Recent Development
Table 98. Vertex Pharmaceuticals Company Details
Table 99. Vertex Pharmaceuticals Business Overview
Table 100. Vertex Pharmaceuticals Direct-acting Antiviral Drugs Product
Table 101. Vertex Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 102. Vertex Pharmaceuticals Recent Development
Table 103. Natco Pharma Company Details
Table 104. Natco Pharma Business Overview
Table 105. Natco Pharma Direct-acting Antiviral Drugs Product
Table 106. Natco Pharma Revenue in Direct-acting Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 107. Natco Pharma Recent Development
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
Table 111. Authors List of This Report
List of Figures
Figure 1. Direct-acting Antiviral Drugs Picture
Figure 2. Global Direct-acting Antiviral Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Direct-acting Antiviral Drugs Market Share by Type: 2024 VS 2031
Figure 4. NS3/4A Protease Inhibitors Features
Figure 5. Nucleoside and Nucleotide NS5B Polymerase Inhibitors Features
Figure 6. NS5A Inhibitors Features
Figure 7. Non-Nucleoside NS5B Polymerase Inhibitors Features
Figure 8. Global Direct-acting Antiviral Drugs Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Direct-acting Antiviral Drugs Market Share by Application: 2024 VS 2031
Figure 10. Hospitals Case Studies
Figure 11. Clinics Case Studies
Figure 12. Ambulatory Surgical Centers Case Studies
Figure 13. Pharmacies Case Studies
Figure 14. Others Case Studies
Figure 15. Direct-acting Antiviral Drugs Report Years Considered
Figure 16. Global Direct-acting Antiviral Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 17. Global Direct-acting Antiviral Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 18. Global Direct-acting Antiviral Drugs Market Share by Region: 2024 VS 2031
Figure 19. Global Direct-acting Antiviral Drugs Market Share by Players in 2024
Figure 20. Global Top Direct-acting Antiviral Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Direct-acting Antiviral Drugs as of 2024)
Figure 21. The Top 10 and 5 Players Market Share by Direct-acting Antiviral Drugs Revenue in 2024
Figure 22. North America Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. North America Direct-acting Antiviral Drugs Market Share by Country (2020-2031)
Figure 24. United States Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Canada Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Europe Direct-acting Antiviral Drugs Market Share by Country (2020-2031)
Figure 28. Germany Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. France Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. U.K. Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Italy Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Russia Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Nordic Countries Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific Direct-acting Antiviral Drugs Market Share by Region (2020-2031)
Figure 36. China Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Japan Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. South Korea Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Southeast Asia Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. India Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Australia Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Latin America Direct-acting Antiviral Drugs Market Share by Country (2020-2031)
Figure 44. Mexico Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Brazil Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Middle East & Africa Direct-acting Antiviral Drugs Market Share by Country (2020-2031)
Figure 48. Turkey Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Saudi Arabia Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. UAE Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. AbbVie Inc. Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2020-2025)
Figure 52. GSK Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2020-2025)
Figure 53. Boehringer Ingelheim Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2020-2025)
Figure 54. Merck Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2020-2025)
Figure 55. Novartis Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2020-2025)
Figure 56. Beximco Pharmaceuticals Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2020-2025)
Figure 57. Roche Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2020-2025)
Figure 58. Bristol-Myers Squibb Company Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2020-2025)
Figure 59. Gilead Sciences Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2020-2025)
Figure 60. Janssen (Johnson & Johnson) Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2020-2025)
Figure 61. Vertex Pharmaceuticals Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2020-2025)
Figure 62. Natco Pharma Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2020-2025)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Table 1. Global Direct-acting Antiviral Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of NS3/4A Protease Inhibitors
Table 3. Key Players of Nucleoside and Nucleotide NS5B Polymerase Inhibitors
Table 4. Key Players of NS5A Inhibitors
Table 5. Key Players of Non-Nucleoside NS5B Polymerase Inhibitors
Table 6. Global Direct-acting Antiviral Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Direct-acting Antiviral Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Direct-acting Antiviral Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Direct-acting Antiviral Drugs Market Share by Region (2020-2025)
Table 10. Global Direct-acting Antiviral Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Direct-acting Antiviral Drugs Market Share by Region (2026-2031)
Table 12. Direct-acting Antiviral Drugs Market Trends
Table 13. Direct-acting Antiviral Drugs Market Drivers
Table 14. Direct-acting Antiviral Drugs Market Challenges
Table 15. Direct-acting Antiviral Drugs Market Restraints
Table 16. Global Direct-acting Antiviral Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Direct-acting Antiviral Drugs Market Share by Players (2020-2025)
Table 18. Global Top Direct-acting Antiviral Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Direct-acting Antiviral Drugs as of 2024)
Table 19. Ranking of Global Top Direct-acting Antiviral Drugs Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Direct-acting Antiviral Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Direct-acting Antiviral Drugs, Headquarters and Area Served
Table 22. Global Key Players of Direct-acting Antiviral Drugs, Product and Application
Table 23. Global Key Players of Direct-acting Antiviral Drugs, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Direct-acting Antiviral Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Direct-acting Antiviral Drugs Revenue Market Share by Type (2020-2025)
Table 27. Global Direct-acting Antiviral Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Direct-acting Antiviral Drugs Revenue Market Share by Type (2026-2031)
Table 29. Global Direct-acting Antiviral Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Direct-acting Antiviral Drugs Revenue Market Share by Application (2020-2025)
Table 31. Global Direct-acting Antiviral Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Direct-acting Antiviral Drugs Revenue Market Share by Application (2026-2031)
Table 33. North America Direct-acting Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Direct-acting Antiviral Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Direct-acting Antiviral Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Direct-acting Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Direct-acting Antiviral Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Direct-acting Antiviral Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Direct-acting Antiviral Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Direct-acting Antiviral Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Direct-acting Antiviral Drugs Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Direct-acting Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Direct-acting Antiviral Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Direct-acting Antiviral Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Direct-acting Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 48. AbbVie Inc. Company Details
Table 49. AbbVie Inc. Business Overview
Table 50. AbbVie Inc. Direct-acting Antiviral Drugs Product
Table 51. AbbVie Inc. Revenue in Direct-acting Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 52. AbbVie Inc. Recent Development
Table 53. GSK Company Details
Table 54. GSK Business Overview
Table 55. GSK Direct-acting Antiviral Drugs Product
Table 56. GSK Revenue in Direct-acting Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 57. GSK Recent Development
Table 58. Boehringer Ingelheim Company Details
Table 59. Boehringer Ingelheim Business Overview
Table 60. Boehringer Ingelheim Direct-acting Antiviral Drugs Product
Table 61. Boehringer Ingelheim Revenue in Direct-acting Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 62. Boehringer Ingelheim Recent Development
Table 63. Merck Company Details
Table 64. Merck Business Overview
Table 65. Merck Direct-acting Antiviral Drugs Product
Table 66. Merck Revenue in Direct-acting Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 67. Merck Recent Development
Table 68. Novartis Company Details
Table 69. Novartis Business Overview
Table 70. Novartis Direct-acting Antiviral Drugs Product
Table 71. Novartis Revenue in Direct-acting Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 72. Novartis Recent Development
Table 73. Beximco Pharmaceuticals Company Details
Table 74. Beximco Pharmaceuticals Business Overview
Table 75. Beximco Pharmaceuticals Direct-acting Antiviral Drugs Product
Table 76. Beximco Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 77. Beximco Pharmaceuticals Recent Development
Table 78. Roche Company Details
Table 79. Roche Business Overview
Table 80. Roche Direct-acting Antiviral Drugs Product
Table 81. Roche Revenue in Direct-acting Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 82. Roche Recent Development
Table 83. Bristol-Myers Squibb Company Company Details
Table 84. Bristol-Myers Squibb Company Business Overview
Table 85. Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Product
Table 86. Bristol-Myers Squibb Company Revenue in Direct-acting Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 87. Bristol-Myers Squibb Company Recent Development
Table 88. Gilead Sciences Company Details
Table 89. Gilead Sciences Business Overview
Table 90. Gilead Sciences Direct-acting Antiviral Drugs Product
Table 91. Gilead Sciences Revenue in Direct-acting Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 92. Gilead Sciences Recent Development
Table 93. Janssen (Johnson & Johnson) Company Details
Table 94. Janssen (Johnson & Johnson) Business Overview
Table 95. Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Product
Table 96. Janssen (Johnson & Johnson) Revenue in Direct-acting Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 97. Janssen (Johnson & Johnson) Recent Development
Table 98. Vertex Pharmaceuticals Company Details
Table 99. Vertex Pharmaceuticals Business Overview
Table 100. Vertex Pharmaceuticals Direct-acting Antiviral Drugs Product
Table 101. Vertex Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 102. Vertex Pharmaceuticals Recent Development
Table 103. Natco Pharma Company Details
Table 104. Natco Pharma Business Overview
Table 105. Natco Pharma Direct-acting Antiviral Drugs Product
Table 106. Natco Pharma Revenue in Direct-acting Antiviral Drugs Business (2020-2025) & (US$ Million)
Table 107. Natco Pharma Recent Development
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
Table 111. Authors List of This Report
List of Figures
Figure 1. Direct-acting Antiviral Drugs Picture
Figure 2. Global Direct-acting Antiviral Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Direct-acting Antiviral Drugs Market Share by Type: 2024 VS 2031
Figure 4. NS3/4A Protease Inhibitors Features
Figure 5. Nucleoside and Nucleotide NS5B Polymerase Inhibitors Features
Figure 6. NS5A Inhibitors Features
Figure 7. Non-Nucleoside NS5B Polymerase Inhibitors Features
Figure 8. Global Direct-acting Antiviral Drugs Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Direct-acting Antiviral Drugs Market Share by Application: 2024 VS 2031
Figure 10. Hospitals Case Studies
Figure 11. Clinics Case Studies
Figure 12. Ambulatory Surgical Centers Case Studies
Figure 13. Pharmacies Case Studies
Figure 14. Others Case Studies
Figure 15. Direct-acting Antiviral Drugs Report Years Considered
Figure 16. Global Direct-acting Antiviral Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 17. Global Direct-acting Antiviral Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 18. Global Direct-acting Antiviral Drugs Market Share by Region: 2024 VS 2031
Figure 19. Global Direct-acting Antiviral Drugs Market Share by Players in 2024
Figure 20. Global Top Direct-acting Antiviral Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Direct-acting Antiviral Drugs as of 2024)
Figure 21. The Top 10 and 5 Players Market Share by Direct-acting Antiviral Drugs Revenue in 2024
Figure 22. North America Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. North America Direct-acting Antiviral Drugs Market Share by Country (2020-2031)
Figure 24. United States Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Canada Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Europe Direct-acting Antiviral Drugs Market Share by Country (2020-2031)
Figure 28. Germany Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. France Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. U.K. Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Italy Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Russia Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Nordic Countries Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific Direct-acting Antiviral Drugs Market Share by Region (2020-2031)
Figure 36. China Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Japan Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. South Korea Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Southeast Asia Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. India Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Australia Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Latin America Direct-acting Antiviral Drugs Market Share by Country (2020-2031)
Figure 44. Mexico Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Brazil Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Middle East & Africa Direct-acting Antiviral Drugs Market Share by Country (2020-2031)
Figure 48. Turkey Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Saudi Arabia Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. UAE Direct-acting Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. AbbVie Inc. Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2020-2025)
Figure 52. GSK Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2020-2025)
Figure 53. Boehringer Ingelheim Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2020-2025)
Figure 54. Merck Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2020-2025)
Figure 55. Novartis Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2020-2025)
Figure 56. Beximco Pharmaceuticals Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2020-2025)
Figure 57. Roche Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2020-2025)
Figure 58. Bristol-Myers Squibb Company Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2020-2025)
Figure 59. Gilead Sciences Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2020-2025)
Figure 60. Janssen (Johnson & Johnson) Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2020-2025)
Figure 61. Vertex Pharmaceuticals Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2020-2025)
Figure 62. Natco Pharma Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2020-2025)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Electrolytes for Lithium-Ion Batteries Market Research Report 2025
Jul 14, 25
Global Vanadium Products Market Research Report 2025
Jul 14, 25
Global High-purity Vanadium Oxide Market Research Report 2025
Jul 14, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232